cmAngio® vs AVIEW
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary goal is to leverage existing mammography workflows to assess cardiovascular risk in women. This tool is specifically designed for the AI-powered detection of Breast Arterial Calcifications (BAC) on both FFDM and DBT exams, providing valuable insights into cardiovascular health without additional radiation or procedures. It's ideal for integrating a cardiovascular risk assessment into routine breast imaging practices.
View cmAngio® →Choose AVIEW if…
Choose AVIEW if you require a comprehensive AI platform for multi-faceted analysis of thoracic CT scans, encompassing lung cancer, COPD, and coronary artery calcification. This solution excels in detailed quantification of lung nodules, emphysema, and coronary artery calcium scoring, offering advanced 3D visualizations and workflow automation. It is best suited for radiology departments needing a robust tool for early detection, diagnosis, and monitoring across multiple cardiopulmonary conditions from CT imaging.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | AVIEW |
|---|---|---|
| Pricing | Paid, out-of-pocket | Subscription; one-off payment |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWWhile Tool A emphasizes quick installation and DICOM compatibility, Tool B demonstrates a more advanced focus on user experience and workflow integration. Its 'zero-click' workflow, optimized UI/UX, and comprehensive reporting directly address efficiency and ease of use within existing radiology environments, making it more user-friendly for daily clinical practice.
Clinical Value
AVIEWTool B offers a significantly broader and deeper clinical value by addressing multiple major diseases (lung cancer, COPD, CAC) with advanced quantification, characterization, and workflow efficiency improvements. While Tool A provides valuable insights into cardiovascular risk from mammograms, Tool B's comprehensive multi-disease platform with proven impact on throughput and diagnostic precision offers greater overall clinical utility.
Pricing & Value
AVIEWTool B provides greater transparency regarding its pricing models (subscription, one-off payment, based on installations/users), which allows potential customers to better understand the cost structure. Although specific figures are not public, this clarity, coupled with claims of measurable ROI through increased efficiency and follow-up exams, suggests a more defined value proposition compared to Tool A's opaque pricing.
Enterprise Readiness
AVIEWBoth tools are FDA-cleared and HIPAA-compliant, but Tool B significantly surpasses Tool A in enterprise readiness due to its extensive and flexible deployment options (cloud, hybrid, local, virtualized). Its explicit and proven integration with PACS/RIS/CIS, along with global adoption in large-scale screening programs and validation against industry standards like IHE and FHIR, demonstrates a superior capability for seamless enterprise-level implementation.
Innovation
AVIEWWhile Tool A is innovative in its specific application of AI to mammography for cardiovascular risk, Tool B demonstrates broader and deeper innovation. Its integrated diagnostic ecosystem, combining multiple complex analyses (lung cancer, COPD, CAC, ILD) from a single CT scan with advanced quantification, 3D visualization, and workflow automation, represents a more comprehensive and transformative approach to AI in medical imaging.
Support & Docs
TieNeither the provided structured facts nor the web search results offer specific details regarding the availability, quality, or channels for customer support and documentation for either tool. Without this crucial information, it is not possible to differentiate between the two products on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | AVIEW |
|---|---|---|
| Name | cmAngio® | AVIEW |
| Company | CureMetrix | Coreline Soft Co. |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | AI platform offering comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows. |
| Primary Focus | Breast Arterial Calcifications (BAC) detection on mammograms | Lung cancer, COPD, and coronary artery calcification from CT scans |
| Key Features (Cardiology) | AI-based detection of Breast Arterial Calcifications (BAC), Provides visualization of BAC location on a scorecard, Enables BAC identification and reporting without additional radiation or procedures | Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification), Automated segmentation of coronary arteries |
| Key Features (Radiology/Imaging) | Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams, Compatible with any DICOM-compliant viewer, Adjustable operating point to meet clinical goals, Quick and easy installation (less than an hour) | AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score), Emphysema quantification and low attenuation area (LAA) analysis, Automated segmentation of lung lobes, airways, vessels, 3D visualizations and comprehensive PDF reports, Workflow automation and integration with PACS/RIS/CIS, Follow-up registration and nodule matching for serial CT scans, Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture) |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and AVIEW.